首页|肿瘤治疗性mRNA疫苗非临床评价的考虑

肿瘤治疗性mRNA疫苗非临床评价的考虑

扫码查看
肿瘤治疗性mRNA疫苗作为一种新型肿瘤治疗方式受到广泛关注,目前多数产品正处于临床前或临床研究阶段,国内外尚无成熟的产品上市.由于肿瘤治疗性mRNA疫苗的靶点特性、作用机制、递送特征,以及人体与动物免疫系统存在的差异,使得此类产品在非临床试验设计和评价中情况更复杂.其中动物模型的选择不仅是非临床有效性关注的内容,也是毒性评价的关键考虑因素.本文从肿瘤治疗性mRNA疫苗产品非临床试验设计的角度,根据此类产品自身特点,通过分析、总结已开展临床产品的非临床研究,结合相关指导原则,探讨此类产品非临床评价关注的问题.
Consideration on the non-clinical evaluation of therapeutic mRNA vaccines for tumors
Therapeutic mRNA vaccine for tumors attracted much attention as a new type of tumor treatment,and most products are in the preclinical and clinical research stage,and there has not post-market drug.However,the non-clinical evaluation of therapeutic mRNA vaccines for tumors is more complicated,due to their target features,mechanisms,delivery patterns,and the cross-species differences of immune system.The choice of animal model is not only content of the clinical effectiveness,and it was a key factor of toxicity assessment.In this work,the challenges for non-clinical evaluation of therapeutic mRNA vaccines for tumors are discussed,and the compliant requirements are reviewed,and the general considerations are suggested.

therapeutic mRNA vaccine for tumorsnon-clinical evaluationanimal model

吴爽、王寅、尹华静、李峥、尹茂山、于冰

展开 >

国家药品监督管理局药品审评中心,北京 100076

肿瘤治疗性mRNA疫苗 非临床研究 动物模型

2024

中国临床药理学杂志
中国药学会

中国临床药理学杂志

CSTPCD北大核心
影响因子:1.91
ISSN:1001-6821
年,卷(期):2024.40(20)